Variables | Training cohort | Validation cohort | ||||||
---|---|---|---|---|---|---|---|---|
Case | HR | 95% CI | P-value | Case | HR | 95% CI | P-value | |
Univariate analysis | ||||||||
Age | ||||||||
≤ 60a | 100 | 1.0 | 78 | 1.0 | ||||
>60 | 70 | 1.751 | 1.059–2.895 | 0.029 | 54 | 1.195 | 0.620–2.301 | 0.595 |
Gender | ||||||||
Female | 109 | 1.0 | 88 | 1.0 | ||||
Male | 61 | 0.992 | 0.588–1.672 | 0.975 | 44 | 1.316 | 0.673–2.574 | 0.422 |
WHO grade | ||||||||
G1/2 | 56 | 1.0 | 38 | 1.0 | ||||
G3 | 114 | 1.265 | 0.723–2.214 | 0.411 | 94 | 1.911 | 0.836–4.364 | 0.125 |
Tumor size(cm) | ||||||||
≤ 5b | 91 | 1.0 | 97 | 1.0 | ||||
>5 | 79 | 1.758 | 1.060–2.916 | 0.029* | 35 | 2.165 | 1.116–4.203 | 0.022 |
T status | ||||||||
T1/2 | 37 | 1.0 | 44 | 1.0 | ||||
T3/4 | 133 | 7.234 | 2.264–23.119 | 0.001* | 88 | 2.304 | 1.008–5.264 | 0.048* |
N status | ||||||||
N0 | 58 | 1 | 61 | 1 | ||||
N1 | 112 | 3.722 | 1.833–7.558 | < 0.001 | 71 | 3.823 | 1.738–8.409 | 0.001* |
Clinical stage | ||||||||
I + II | 69 | 1 | 70 | 1 | ||||
III | 101 | 4.677 | 2.371–9.227 | < 0.001 | 62 | 4.308 | 2.022–9.180 | < 0.001* |
C12orf59 expression | ||||||||
Low expression | 102 | 1.0 | 79 | 1.0 | ||||
High expression | 68 | 13.497 | 6.790–26.832 | < 0.001* | 53 | 3.326 | 1.680–6.582 | 0.001* |
Multivariate analysis | ||||||||
Age | ||||||||
≤ 60a | 100 | 1.0 | 78 | 1.0 | ||||
>60 | 70 | 0.98 | 0.580–1.657 | 0.941 | 54 | 1.021 | 0.520–2.007 | 0.952 |
T status | ||||||||
T1/2 | 37 | 1.0 | 44 | 1.0 | ||||
T3/4 | 133 | 6.351 | 1.944–20.752 | 0.002 | 88 | 1.35 | 0.568–3.210 | 0.497 |
N status | ||||||||
N0 | 58 | 1.0 | 61 | 1.0 | ||||
N1 | 112 | 1.690 | 0.818–3.489 | 0.156 | 71 | 2.875 | 1.269–6.512 | 0.011* |
Tumor size(cm) | ||||||||
≤ 5b | 91 | 1.0 | 97 | 1.0 | ||||
>5 | 79 | 1.405 | 0.832–2.374 | 0.203 | 35 | 1.404 | 0.701–2.810 | 0.338 |
C12orf59 expression | ||||||||
Low expression | 102 | 1.0 | 79 | 1.0 | ||||
High expression | 68 | 13.012 | 6.402–26.446 | < 0.001* | 53 | 2.656 | 1.311–5.380 | 0.007* |